Interleukin 17: An unlikely marker of acute coronary syndrome?
KD Patel, RT Murphy, M White… - …, 2009 - atherosclerosis-journal.com
Recent studies have shown that the IL-23/IL-17 pathway, which is recognised to be involved
in pathological conditions such as inflammatory bowel disease, may be a novel therapeutic
target [1, 2]. With the role of inflammation being well recognised in the setting of
atherosclerotic disease, acute coronary syndromes (ACS) have been associated with an
inflammatory response, and elevated cytokine levels have been associated with an adverse
outcome. Of late, the novel Interleukin 17 axis has been investigated in acute coronary …
in pathological conditions such as inflammatory bowel disease, may be a novel therapeutic
target [1, 2]. With the role of inflammation being well recognised in the setting of
atherosclerotic disease, acute coronary syndromes (ACS) have been associated with an
inflammatory response, and elevated cytokine levels have been associated with an adverse
outcome. Of late, the novel Interleukin 17 axis has been investigated in acute coronary …